Table of Contents

MOOD STATE

CAA Module

Resident_____ **Date**_____

Triggers:		**Check if applicable**
D	Sign or symptom of a mood problem, total mood score	
V0100E	Prior assessment mood interview total severity score	
V0100F	Prior assessment staff assessment of mood total severity score	
Evaluate:		
A1600	Entry date	
B0200-B1000	Sensory deficit	
C0200-C1000	Cognitive deficit or decline	
C1300	Delirium	
D	Insomnia	
D0700	Social Isolation	
E	Behavioral problem, Psychosis	
F	Daily preferences, Psychosocial Well-Being	
G	Decline in ADLs	
I0100	Cancer	
I0200-I0900	Cardiac disease	
I2900-I3400	Metabolic disorder	
I4200-I5500	Neurological disorder	
15700-I6100	Psychiatric diagnosis	
J0300, J0800	Pain	
J1400	Terminal Condition	
N0415	Psychotropic or Opioid use	
P0100, P0200	Restraint	
Use of medication known to cause mood shifts		
Worried expression, Crying, tearfulness		
Complete medication review		
Abnormal laboratory results		
Isolation		
Proceed with care-planning		
Do not proceed with care-planning		
Underlying Causes / Complicating factors / Risks / Referrals **Comments:**		

RESIDENT_____

DATE	PROBLEM	GOAL	TO DATE	INTERVENTIONS	RESP DISC
	Medication Potential for discomfort and side effects related to the use of Antidepressant Alpha-adrenoceptor antagonist, Mirtazepine Dopamine-reuptake blocking compounds / Bupropion Monoamine oxidase inhibitors - MAOIs Serotonin 5-HT 2 Antagonist Nefazodone / Trazodone Selective serotonin-norepinephrine reuptake inhibitors SNRIs Duloxetine / Venlafaxine Selective serotonin reuptake inhibitors SSRIs Citalopram / Escitalopram Fluoxetine / Ffluvoxamine Paroxetine Sertraline Tricyclic (TCA) and related compounds	Resident will be free of any discomfort or adverse side effects		Administer medication as ordered Ask physician to review medication for possible dose reduction every three months Report pertinent lab results to physician Observe for possible side effects every shift Monitor Dosage - Use of two or more antidepressants simultaneously may increase risk of side effects. Monitor Duration - Prior to discontinuation may need a gradual dose reduction to avoid a withdrawal syndrome. Monitor closely for worsening of depression and/or suicidal behavior or thinking, especially during initiation of therapy and during any change in dosage. Monitor for Interactions/Adverse Consequences: Dizziness, nausea, diarrhea, anxiety, nervousness, insomnia, somnolence, weight gain, anorexia Monitor risk for falls. Bupropion may increase seizure risk and be associated with seizures in susceptible individuals. SSRIs in combination with other medications affecting serotonin may increase the risk for serotonin syndrome and seizures.	